NCT01805544View on ClinicalTrials.gov

Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication

CompletedOBSERVATIONAL
Enrollment

113

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

June 30, 2015

Conditions
Venous Thrombosis
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY